The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients

Hematology

Volumn 17, Issue 3, 2012, Pages 183-186

  Mirbehbahani, Narges ^a   Jahazi, Azam ^b   Abad, Hanif Hashem Nejad Rahim ^a  

^a GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Beta thalassemia; Combined therapy; Deferiprone; Deferoxamine; Ferritin

Indexed keywords

ALANINE AMINOTRANSFERASE; DEFERIPRONE; DEFEROXAMINE; FERRITIN; LIVER ENZYME;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHROPATHY; ARTICLE; BETA THALASSEMIA; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; MALE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; DEFEROXAMINE; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; MALE; PYRIDONES;

EID: 84863094697     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13376952196610     Document Type: Article

References (33)

1. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26-36.
2. Zurlo MG, De Stefano P, Borgna-Pignatti A, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2:27-30.
3. Oliveri NF, Nathan DG, MacMilan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta- thalassemia. N Engl J Med. 1994;331:574-578.
4. Sonakul D, Thakerngpol K, Pacharee P, Cardiac pathology in 76 thalassemic patients. Birth Defects Orig Article Ser. 1988;23: 177-191.
5. Barman Balfour JA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs. 1999;58: 553-58.
6. Oliver NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-61.
7. Benz EJ. Hemoglobinopathies. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL (eds.) Harrison's principles of internal medicine. 15th ed. New York: MacGraw-Hill; 2001. p. 668-64.
8. Etone JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med. 2002;32:833-880.
9. Brittenham GM, Griffith PM, Neinhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia. N Engl J Med. 1994;331:567-573.
10. Oliveri NF. Long-term therapy with deferiprone. Acta Haematol. 1996;95:37-48.
11. Al-refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Norty P, Kontoghiorghes GJ. Efficacy and possible adverse effects of the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood. 1992;80:593-599.
12. Modell B. Ethical aspects of genetic screening. Ann Med. 1992; 24:549-555.
13. Porter J. Oral iron chelators: prospect for future development. Eur J Haematol. 1989;43:271-285.
14. Oliveri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314:869-873.
15. Berdoukas V, Dakin C, Freeman A, Fraser I, Aessopos A, Bohane T. Transfusion iron overload cardiac dysfunction: lake of correlation with needle liver biopsy iron concentration. Haematologica. 2005;90:685-686.
16. Kontoghiorghes GJ, Bartlett AN, Sheppard L, Barr J, Nortey P. Oral iron chelation therapy with deferiprone. Monitoring of biological, drug and iron excretion changes. Arzneimittelforschung. 1995;45:65-69.
17. Liu ZD, Khodr DY, Lu SL, Hider RC. Synthesis, physicochemical characterization, and biological evaluation of 2-(1′-hydroxyalkyl)- 3-hydroxypiridin-4-ones: novel iron chelators with enhanced pFe(3+) values. J Med Chem. 1999;42:4814-4823.
18. Apotex Research Inc. An open label, single-dose, three-way crossover bioavailability study of deferiprone tablets (Ferriprox) and deferiprone solution under fasting and fed conditions. Clinical study report. Toronto, Canada; 2005.
19. Al-Rafaie FN, Wilkes S, Wonke B, Hoffbrand AV. The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system. Br J Haematol. 1994;87(1):196-198.
20. Hoffbrand AV. Oral iron chelation. Semin Hematol. 1996;33: 1-8.
21. Gomber S, Bina P, Agus A, Cruba G. Combined therapy with deferiprone and desferoxamine in thalassemia major. Haematologica. 2005;90:1309-1314.
22. Balveer K, Pyra K, Wonke B. Combined oral and parenteral iron chelation in beta thalassaemia major. Med J Malaysia. 2000;55: 493-497.
23. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferioxamine. Br J Haematol. 1998;103: 361-364.
24. Kattamis A, Kassou C, Ladis V, Berdousi H, Papasotiriou I, Kattamis C. Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patient with thalassemia. Blood. 2002;100:120-124.
25. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AL, Taher A. Comparison between desferrioxamin and combined therapy with desferrioxamin and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003; 121:187-189.
26. El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol. 2008; 87:545-550.
27. Farmaki K, Anagnostopoulos G, Platis O, Gotsis E, Toulas P. Combined chelating therapy in patients with thalassaemia major. A fast and effective method of reducing ferritin levels and cardiological complications. Hematol J. 2002;3(Suppl):79.
28. Taher A, Aoun E, Shahare AL, Mourad F, Gharzuddine W, Koussa S, et al. Five year trial of deferiprone chelation therapy in thalassaemia major patients. Acta Haematol. 2004;112: 179-183.
29. Tondury P, Knotojhihiorghes GJ, Iuthy A, Hirta A, Hoffbrand AV. L1 (1,2 dimethyl 1-3 hydroxy prid-4-one) for oral iron chelation in patients with beta-thalassemia major. Haematol J. 1990; 76:550-553.
30. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85:315-319.
31. Hashemieh M, Khosravi Sh. Determining the efficacy of deferiprone (L1) on decreasing ferritin levels of thalassemia patients in Arak city. J Arak Med Sci Univ. 2008;1(42):p1-7 [Persian].
32. th International Conference on Oral Chelation in the Treatment of Thalassaemia Major and Other Diseases; 2001 Mar 22-25; Catania, Italy.
33. Huang X-P, Spino M, Thiessen JJ. Transport kinetics of iron chelators and their chelates in Caco-2 cells. Pharm Res. 2006;23: 280-290.